Over the past several decades, asbestos has become vital in military environments, as this natural mineral was used extensively to construct barracks, vehicles, and other assets. Yet its widespread ...

The malignant pleural mesothelioma market is poised for steady growth during the forecast period (2025–2034). The launch of innovative therapies by companies such as AstraZeneca, Polaris ...

Pleural mesothelioma, specifically, is the most common type of mesothelioma, and it affects the mesothelial lining around the lungs. Why Are the Symptoms of Pleural Mesothelioma So Hard to Spot?

Lung cancer and pleural mesothelioma are often confused, so it’s important to understand the key differences between them, including tumor location and treatments.

Malignant pleural mesothelioma molecular pathology, diagnosis, and treatment modalities are described in this article.

Fintel reports that on July 8, 2025, Ladenburg Thalmann initiated coverage of NovoCure (NasdaqGS:NVCR) with a Buy ...

Dr. Hedy Kindler joins us on the podcast to discuss the latest update to the treatment of pleural mesothelioma guideline. She discusses the latest changes to the updated recommendations across topics ...

Pleural mesothelioma (PM) is mainly caused by asbestos exposure and characterized by poor prognosis and limited therapeutic options. A recent research study identified the oncoprotein YB-1 as an ...

What are some of the most common symptoms of mesothelioma? Pleural mesothelioma – a type of cancer caused by asbestos in the lining of the lungs – is the most common type of this disease.

Mesothelioma is a rare but almost always fatal form of cancer linked to asbestos exposure. It is predominantly detected among ...

The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.

After a long period of neglect, malignant pleural mesothelioma has received the necessary attention by the oncological community over the past decade. Major molecular drivers of the disease have ...